Senior Vice President and Chief Clinical Development Officer · Kiniksa Pharmaceuticals International, plc (KNSA)

Arian Pano

FY2021 is the first fiscal year CompBrief holds for Arian Pano as a named executive officer of Kiniksa Pharmaceuticals International; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,372,110

Salary $436,000Stock awards $204,677

3rd of 3 named executive officers at Kiniksa Pharmaceuticals International by FY2021 total.

3 named officers on file for Kiniksa Pharmaceuticals International, FY2021

Arian Pano’s pay file — $29

  • 1 fiscal year of pay, line by line
  • KNSA’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kiniksa Pharmaceuticals International’s whole pay program stands against its peers

  • Kiniksa Pharmaceuticals International’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KNSA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A).

Free

Get Arian Pano’s full pay file as a PDF — free

More than this page: up to 10 years of Arian’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Arian Pano compensation by year

Kiniksa Pharmaceuticals International Summary Compensation Table · the one fiscal year held
In US dollars, as Kiniksa Pharmaceuticals International reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$436,000
Bonus$0
Stock awards$204,677
Option awards$561,493
Non-equity incentive$158,340
Pension and deferred compensation$0
All other$11,600
Total$1,372,110

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kiniksa Pharmaceuticals International, plc DEF 14A filed April 28, 2022, accession 0001104659-22-052344, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kiniksa Pharmaceuticals International, plc filed document, accession 0001104659-22-052344. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU4,867$57,285—
RSU3,888$45,762—
RSU3,888$45,762—
RSU3,240$38,135—
Option16,874—$15.52
Option47,915—$10.14
Option20,624—$15.50
Option23,325—$22.89
Option23,325—$12.97

Per the Outstanding Equity Awards at Fiscal Year-End table in Kiniksa Pharmaceuticals International, plc's FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Kiniksa Pharmaceuticals International’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Sanj PatelChief Executive Officer and Chairman of the Board$6,588,178
John PaoliniSenior Vice President and Chief Medical Officer$2,028,830
Arian Pano · this pageSenior Vice President and Chief Clinical Development Officer$1,372,110

The full Kiniksa Pharmaceuticals International compensation record

free company brief

This page is one person within Kiniksa Pharmaceuticals International's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Kiniksa Pharmaceuticals International proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kiniksa Pharmaceuticals International's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Arian Pano's compensation dossier · One-time report. No refunds.